Zenas BioPharma (ZBIO) Change in Accured Expenses (2023 - 2026)

Zenas BioPharma's Change in Accured Expenses history runs 4 years deep, the most recent figure standing at -$5.0 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 55.55% year-over-year to -$5.0 million in Q1 2026; TTM through Mar 2026 was $21.3 million, a 126.11% increase from a year earlier, with the FY2025 full-year figure at $15.1 million, down 31.78% from the prior year.
• Change in Accured Expenses fell to -$5.0 million in Q1 2026 per ZBIO's latest filing, from $9.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $16.3 million in Q2 2025 and bottomed at -$11.2 million in Q1 2025.
• The 4-year median for Change in Accured Expenses is $2.4 million (2023), against an average of $3.5 million.
• Biggest YoY gain for Change in Accured Expenses was 1781.86% in 2025; the steepest drop was 844.33% in 2025.
• Year by year, Change in Accured Expenses stood at $3.2 million in 2023, then jumped by 267.0% to $11.9 million in 2024, then decreased by 17.4% to $9.8 million in 2025, then sank by 150.64% to -$5.0 million in 2026.
• Per Business Quant, the three latest ZBIO Change in Accured Expenses figures stand at -$5.0 million (Q1 2026), $9.8 million (Q4 2025), and $102000.0 (Q3 2025).